Vancomycin

CHEMBL262777 Phase 4 已批准 Small molecule
Half-Life
4-6 hours
Bioavailability
Protein Binding
Molecular Weight
1449.2 g/mol
LogP
-2.6
Phase
4

This powerful glycopeptide antibiotic is used intravenously to treat serious bacterial infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and is taken orally specifically to treat Clostridioides difficile (C. diff) colitis. It is typically reserved for infections resistant to other antibiotics due to concerns about resistance. Blood levels, kidney function, and hearing must be carefully monitored during intravenous treatment.

分子量

1449.2500 g/mol

LogP

-2.60

TPSA

530.00 Ų

Lipinski 五规则

不符合

治疗领域

药物分类

作用机制

Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.

Pharmacokinetics (PK)

Half-Life 4-6 hours

Pharmacodynamics (PD)

机制

Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O

InChI

InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1

Molecular Formula

C66H75Cl2N9O24

HBD / HBA

19 / 26

可旋转键数

13

重原子数

101

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This powerful glycopeptide antibiotic is used intravenously to treat serious bacterial infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and is taken orally specifically to treat Clostridioides difficile (C. diff) colitis. It is typically reserved for infections resistant to other antibiotics due to concerns about resistance. Blood levels, kidney function, and hearing must be carefully monitored during intravenous treatment.

Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.

Key pharmacokinetic parameters for Vancomycin: Half-life: 4-6 hours.

Yes, Vancomycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL262777. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 14969. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.